Research location
Candiolo
Italy
Advertisement
Research activity in Candiolo
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 61 trials and 61 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Candiolo
61 linked trials · page 1 of 2A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsNCT07407933 · 2026-03-31 · 1 site observation
RECRUITING
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerNCT07288177 · 2026-01-30 · 1 site observation
RECRUITING
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World SettingNCT07230691 · 2025-12-03 · 1 site observation
RECRUITING
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation
RECRUITING
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24 · 1 site observation
RECRUITING
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation
RECRUITING
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerNCT06892548 · 2025-05-02 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · 2025-04-04 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)NCT06330064 · 2024-04-10 · 1 site observation
RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation
RECRUITING
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT05696626 · 2023-10-31 · 1 site observation
RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410 · 2023-10-18 · 1 site observation
RECRUITING
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsNCT05983432 · 2023-08-08 · 1 site observation
RECRUITING
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerNCT05492682 · 2023-02-02 · 1 site observation
RECRUITING
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerNCT05386108 · 2022-08-31 · 1 site observation
RECRUITING
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)NCT04916613 · 2022-04-19 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)NCT06726265 · 2025-03-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · 2024-11-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationNCT06039384 · 2023-12-28 · 1 site observation
TERMINATED
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerNCT05367440 · 2022-06-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147 · 2021-12-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerNCT05113251 · 2021-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)NCT05104866 · 2021-10-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · 2021-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationNCT04685135 · 2021-02-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775 · 2021-02-17 · 1 site observation
COMPLETED
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · 2020-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · 2020-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibNCT04421963 · 2020-08-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerNCT04494425 · 2020-07-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerNCT04305496 · 2020-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.NCT03286842 · 2018-01-17 · 1 site observation
COMPLETED
MEtronomic TrEatment Option in Advanced bReast cAncerNCT02954055 · 2017-09-13 · 1 site observation
COMPLETED
Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer PatientsNCT02850419 · 2017-03-01 · 1 site observation
WITHDRAWN
Safety of Pregnancy in BRCA Mutated Breast Cancer PatientsNCT03673306 · 2017-01-16 · 1 site observation
COMPLETED
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022 · 2016-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer PatientsNCT03144947 · 2016-11-29 · 1 site observation
UNKNOWN
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1NCT02620280 · 2016-04-01 · 1 site observation
COMPLETED
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)NCT02677896 · 2016-03-09 · 1 site observation
COMPLETED
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerNCT02404051 · 2015-12-01 · 1 site observation
UNKNOWN
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentNCT02485691 · 2015-11-09 · 1 site observation
COMPLETED
Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of TreatmentsNCT02284581 · 2015-11-01 · 1 site observation
UNKNOWN
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNCT02352948 · 2015-01-13 · 1 site observation
COMPLETED
A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate CancerNCT02293707 · 2014-11-01 · 1 site observation
COMPLETED
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNCT02087423 · 2014-02-25 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.